Clinical trials: Dexamethasone
Macular Edema, Retinal Vein Occlusion
Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®
This study will use retrospective data to evaluate the safety and efficacy of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) in the treatment of macular oedema due to retinal vein occlusion (RVO) in clinical practice.
- Trial name
- NCT02181530
- Testing
- No Intervention
- Where
- Poland
- Volunteers
- 43 people
- Sponsor
- Allergan
Ataxia Telangiectasia, Genetic Syndrome
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
Primary Objective To monitor and evaluate the long-term safety and tolerability of EDS-EP in AT patients. Secondary Objective To evaluate the long-term effect of EDS-EP on health-related Quality of Life (QoL; EQ-5D-5L scale).
- Trial name
- OLE-IEDAT (NCT03563053)
- Testing
- EryDex System
- Where
- 17 sites in United States, Australia and 9 more
- Volunteers
- 104 people
- Sponsor
- Quince Therapeutics S.p.A.
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
- Trial name
- NCT06115135
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Oncotherapeutics
Uveitis, Anterior
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment…
- Trial name
- NCT00694135
- Testing
- EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
- Where
- 19 sites in United States, India
- Volunteers
- 40 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Cataract
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
To assess the safety of Dextenza compared to an active control, prednisolone acetate suspension, for the treatment of postoperative pain and inflammation following ocular surgery for pediatric cataract.
- Trial name
- NCT04539548
- Testing
- Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic suspension USP 1%
- Where
- 14 sites in United States
- Volunteers
- 65 people
- Sponsor
- Ocular Therapeutix, Inc.
Blepharoconjunctivitis
Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.
- Trial name
- NCT00754949
- Testing
- 1% Azithromycin and 0.1% Dexamethasone, 1% Azithromycin, 0.1% Dexamethasone
- Sponsor
- Sun Pharmaceutical Industries Limited
Inflammation and Pain Associated With Cataract Surgery
2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.
- Trial name
- ISV-305 (NCT03192150)
- Testing
- ISV-305, Vehicle
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acute Otitis Externa
Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa
The purpose of the study is to demonstrate the clinical therapeutic non-inferiority of EXL CDOS to commercially available Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic Suspension (Ciprodex®, Alcon) in the treatment of…
- Trial name
- NCT02216071
- Testing
- Ciprodex®, EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 499 people
- Sponsor
- Exela Pharma Sciences, LLC.
Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Multi-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion.
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT07387926
- Testing
- Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone
- Where
- 4 sites in Australia, Israel and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Conjunctivitis
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial conjunctivitis.
- Trial name
- NCT03004924
- Testing
- SHP640, PVP-I 0.6%
- Where
- 163 sites in United States, Australia and 11 more
- Volunteers
- 753 people
- Sponsor
- Shire
AL Amyloidosis
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04304144
- Testing
- CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Adenoviral Conjunctivitis
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with adenoviral conjunctivitis.
- Trial name
- NCT02998541
- Testing
- SHP640, PVP-I 0.6%
- Where
- 130 sites in United States, Australia and 14 more
- Volunteers
- 219 people
- Sponsor
- Shire
Blepharoconjunctivitis
Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.
- Trial name
- NCT00578955
- Testing
- 1% Azithromycin and 0.1% Dexamethasone, 1% Azithromycin, 0.1% Dexamethasone
- Volunteers
- 417 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Brain Edema, Brain Tumor
Tolerability Study of Xerecept® in Pediatric Patients
This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.
- Trial name
- NCT01369121
- Testing
- XERECEPT
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celtic Pharma Development Services
Acute Lymphoblastic Leukemia
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
- Trial name
- NCT00144963
- Testing
- Vincristine Sulfate Liposomes Injection, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Acrotech Biopharma Inc.
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma…
- Trial name
- NCT02518113
- Testing
- LY3039478, Dexamethasone
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Urinary Tract Infections in Children, Dexamethasone
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with…
- Conditions
- Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis
- Trial name
- NCT04654507
- Testing
- Dexamethasone Oral
- Where
- Qatar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Otitis Media in Patients With Tympanostomy Tubes
Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes
The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par) to the already-marketed formulation CIPRODEX®…
- Trial name
- NCT01994642
- Testing
- Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension, CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
- Where
- 23 sites in United States
- Volunteers
- 203 people
- Sponsor
- Par Pharmaceutical, Inc.
Dry Eye
Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye
The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.
- Trial name
- NCT01129856
- Testing
- Dexamethasone phosphate ophthalmic solution, Sodium citrate buffer solution
- Where
- 5 sites in United States
- Volunteers
- 198 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Active, Symptomatic Blepharitis
Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.
- Trial name
- ISV-305 (NCT01543490)
- Testing
- ISV-305, Vehicle
- Where
- United States
- Volunteers
- 558 people
- Sponsor
- Sun Pharmaceutical Industries Limited